Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05411016
NCT05411016Active, not recruitingPhase 1

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers, Patient With Systemic Lupus Erythematosus, and Patient With Cutaneous Lupus Erythematosus

Kyowa Kirin Co., Ltd.23 sites in 2 countries116 target enrollmentStarted: August 3, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
116
Locations
23
Primary Endpoint
Number of participants with adverse events (AEs)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Part 1 : To evaluate the safety and tolerability of a single intravenous (IV) or subcutaneous (SC) dose of KK4277 in healthy Japanese or non-Asian adult males.

Part 2 : To evaluate the safety and tolerability of repeated IV administration of KK4277 in patients with Systemic lupus erythematosus (SLE) or Cutaneous lupus erythematosus (CLE).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description

Outcomes Assessor: pharmacokinetic person, pharmacodynamic analysis person and investigational drug administration person are unblinded.

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Voluntary written informed consent to participate in the study
  • •Japanese or non-Asian healthy men 18 to < 50 years at the time of informed consent
  • •BMI 18.5 to < 30.0 at screening
  • •Inclusion Criteria: Part 2
  • •Voluntary written informed consent to participate in the study
  • •Age 18 years to < 75 years at the time of informed consent
  • •Weight over 40 kg and BMI 18.5 to < 35.0 at screening
  • •Patients who meet any of the following criteria
  • •Patients who meet the EULAR/ACR 2019 SLE classification criteria and have a diagnosis of SLE by screening
  • •Patients with CLE diagnosed by skin biopsy

Exclusion Criteria

  • •Current illness requiring treatment
  • •History of or current respiratory disease, heart disease, gastrointestinal disease, kidney disease, liver disease, psychiatric disease, autoimmune disease, or Cancer.
  • •History or of current drug allergy
  • •Exclusion Criteria:Part2
  • •Complications of active lupus nephritis(urinary column (granular column or red blood cell column), hematuria (>5 red blood cells/high power field, excluding other causes such as stones or infection), proteinuria >0.5 g/24 h, pyuria (>5 white blood cells/high power field excluding infection)) or active central nervous lupus (delirium, psychiatric symptoms, seizures, etc.)
  • •Patients with serious complications that are judged by the investigator or sub-investigator to affect the conduct and evaluation of the study.
  • •Patients with bacterial, viral, fungal, or parasitic infections recognized within 28 days prior to obtaining consent
  • •Patients with an infectious disease requiring hospitalization or IV administration of antimicrobial, antiviral, antifungal, or antiparasitic drugs within 24 weeks prior to obtaining consent

Arms & Interventions

Placebo

Placebo Comparator

Intervention: Placebo (Drug)

KK4277

Experimental

Intervention: KK4277 (Drug)

Outcomes

Primary Outcomes

Number of participants with adverse events (AEs)

Time Frame: Part 1 : from Day 1 through at most Day 113, Part 2: from Day 1 through at most Day 169

For adverse events that occurred after administration of the investigational drug, number of subjects with AEs and occurrence frequency are evaluated.

Secondary Outcomes

  • Profile of pharmacokinetics of serum KK4277 concentration(Part 1 : Day 1 (pre-dose, 0, 1, 6 hours after the start of administration), 2, 3, 4, 5, 6, 8, 15, 22, 29, 43, 57, 71, 85, 99, 113, Part 2 :Enrollment, Day1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 141, 169)
  • Time to the maximum concentration(Part 1 : Day 1 to Day 113, Part 2 : Day 1 to Day 169)
  • The maximum concentration(Part 1 : Day 1 to Day 113, Part 2 : Day 1 to Day 169)
  • Area under the concentration-time curve(Part 1 : Day 1 to Day 113, Part 2 : Day 1 to Day 169)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (23)

Loading locations...

Similar Trials

Terminated
Phase 1
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic DermatitisAtopic Dermatitis
NCT03846466Kyowa Kirin Co., Ltd.5
Completed
Phase 1
A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy VolunteersObesity
NCT00509132Genaera Corporation42
Completed
Phase 1
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy VolunteersHealthy Volunteers
NCT03115996Regeneron Pharmaceuticals56
Completed
Phase 1
A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic VolunteersDiabetes MellitusObesity
NCT00606112Genaera Corporation28
Completed
Phase 1
A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative ColitisHealthy Men and Subjects With Ulcerative Colitis
NCT02985593Kyowa Kirin Co., Ltd.155
A Study of KK4277 in Healthy Volunteers... | Clinical Trial